These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9556783)

  • 1. Evolving role of oral chemotherapy for the treatment of patients with neoplasms.
    Greco FA
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):43-50. PubMed ID: 9556783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
    Icli F; Akbulut H; Onur H; Yalcin B; Demirkazık A; Senler FÇ
    Breast; 2011 Apr; 20(2):155-7. PubMed ID: 20951586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemotherapy--present status and problems].
    Furue H
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):589-96. PubMed ID: 10234287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic aspects of oral administration of etoposide].
    Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
    Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
    Todnem K; Harboe K; Zotova L; Lind A; Ogreid D
    Tidsskr Nor Laegeforen; 2000 Sep; 120(23):2781-5. PubMed ID: 11107924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
    Awada A
    Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Etoposide in the treatment of small-cell lung cancer].
    Ueoka H
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1920-4. PubMed ID: 8978798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
    Lebeau B; Chouaïd C; Baud M; Masanès MJ; Febvre M
    Lung Cancer; 2010 Feb; 67(2):188-93. PubMed ID: 19394109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
    Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
    Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats.
    Naik H; Lehr J; Akhtar A; Pienta K
    Anticancer Res; 1994; 14(6B):2681-4. PubMed ID: 7872701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
    Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
    Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of small cell lung cancer with emphasis on oral topotecan.
    Pirker R; Berzinec P; Brincat S; Kasan P; Ostoros G; Pesek M; Plāte S; Purkalne G; Rooneem R; Skricková J; Stanculeanu D; Timcheva C; Tzekova V; Zakotnik B; Zielinski CC; Zwitter M
    Lung Cancer; 2010 Oct; 70(1):7-13. PubMed ID: 20576312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.